Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Size: px
Start display at page:

Download "Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation."

Transcription

1 Pharmacy Law 2016 Ronda H. Lacey, J.D., M.S. Pharm Disclosure Statement I have no conflicts of interest to disclose related to this presentation. Objectives At the conclusion of this continuing education program, each pharmacist and pharmacist consultant will be able to: Identify and explain the changes contained in the ALBOP amendment to the Institutional Pharmacy Rule, 680-X Explain Alabama law(s) dealing with emergency Schedule-II prescriptions; and analyze a case from the Department of Justice dealing with the inappropriate dispensing of Schedule-II medications. Explain Alabama law(s) dealing with emergency prescription refills. Define and discuss the professional legal responsibilities of a pharmacist in dispensing the opioid an antagonist, naloxone hydrochloride, pursuant to ALA. Code

2 Institutional Pharmacies The Alabama State Board of Pharmacy, ALBOP, has amended 680-X-2.18 to allow for the use and operation of automated dispensing systems in skilled nursing facilities under certain conditions. May 5, 2016 was the last day for comments on the rule. Listed as680-x-2.18 (6) Automated Dispensing Systems in Skilled Nursing Facilities. Today we will review some of the major provisions dealing with institutional pharmacies. Institutional Pharmacies Automated Dispensing system: an electromechanical system that performs operations or activities related to the storage and dispensing of medications and which is capable of collecting, controlling and maintaining all required transaction information and records. Institutional Pharmacies Emergency Medication: any medication, including controlled substances, ordered by a licensed prescriber in response to a critical patient need. STAT Medication: any medication, excluding controlled substances, ordered and added to the drug regimen of a newly admitted patient or an existing patient that is not available from the Managing Pharmacy in sufficient time to prevent risk of harm to the patient and that might result from a delay in obtaining such medication. 2

3 Institutional Pharmacies The Board will meet to consider approval for the automated system. The request must be submitted at least 30 days prior to the Board meeting where the request is considered. There must be a managing pharmacy physically located in Alabama responsible for supplying the medication and safe operation of the system. Institutional Pharmacies Must provide a document containing written policies and procedures. Important to note that the automated dispensing system shall be considered an extension of the Managing Pharmacy. Confirm that positive identification will be used to access the medication and information contained in the automated dispensing system. Institutional Pharmacies Restocking Licensed pharmacist Registered pharmacy technician of managing pharmacy Licensed nurse of the facility or Other licensed healthcare personnel approved by ALBOP. On-site physical inventory of contents at least quarterly. 3

4 Review Questions Is a long term care facility required to use an automated dispensing system to improve compliance and minimize diversion? Can the automated dispensing machine be restocked by a LPN if approved by ALBOP? PharMerica Corp. May 2015 the Department of Justice announced a settlement in the amount of $31.5 million dollars against PharMerica Corporation. The lawsuit alleged that PharMerica had dispensed Schedule II controlled drugs without a valid prescription; and that they had violated the False Claims Act by submitting false claims to Medicare for the improperly dispensed drugs. PharMerica Corp. The lawsuit was a whistleblower case under the False Claims Act. The suit was settled and resolved without determination of or admission of liability. U.S. ex rel. Denk v. PharMerica Corp., No. 09-cv-720 (E.D. Wis). 4

5 PharMerica Corp. Allegations included: Dispensing C-II controlled drugs in nonemergency situations without first obtaining a written prescription from a treating physician. Failing to confirm with a physician whether the narcotics were necessary. Enabling nursing home staff to order narcotics and pharmacists to dispense them. Emergency C-II Prescriptions (g) Code of Alabama: In an emergency situation, a pharmacist may dispense a Schedule II controlled substance for a resident of a longterm care facility, a patient receiving hospice services, or a patient receiving home health care services pursuant to an emergency oral prescription transmitted by the practitioner to the dispensing pharmacy. The quantity dispensed pursuant to an emergency oral prescription shall be limited to the amount adequate to treat the patient during the emergency period not to exceed 72 hours. The practitioner, within seven days of the emergency oral prescription, shall provide the dispensing pharmacy with a written prescription for the quantity prescribed. (Acts 1971, No. 1407, p. 2378, 308; Act 1995, No , p. 1565, 1; Act , p. 1358, 1, Act , p. 256, 1.) Emergency C-II There must be: 1. An emergency situation. 2. Oral prescription/order/communication from the prescriber. 3. Amount of medication is limited to the amount necessary to treat the emergency and cannot exceed a 72 hour supply of medication. 4. Federal law required the oral communication must be reduced to writing although not listed in Title 20, please remember to do this! 5. Prescriber must provide a written copy within 7 days. 5

6 Written Prescription A prescription written for a Schedule II narcotic substance to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, subcutaneous, or intraspinal infusion may be transmitted by the practitioner or the agent of the practitioner to the home infusion pharmacy by facsimile. The facsimile shall serve as the original written prescription (b) Written Prescription A prescription written for Schedule II substances for a resident of a long-term care facility may be transmitted by the practitioner or the agent of the practitioner to the dispensing pharmacy by facsimile. The facsimile shall serve as the original written prescription (c) Written Prescription Prescriber may also send an electronic prescription to serve as the written prescription. 6

7 Emergency C-II Can a physician s employee call in an Emergency C-II prescription for a patient in a LTCF? How many days does the prescriber have to provide a written prescription after a verbal Emergency C-II? Emergency Prescription Refills Practitioners may confuse the laws dealing with Emergency Prescription Refills with the laws dealing with Emergency C-II Prescription. Emergency Dispensing Refills Prior existing rx Unable to obtain refill authorization Necessary for pt Dispense a 1 time emergency refill Max: 72 hour supply Not a C-II or C-III Create a written rx Notify prescriber Obtain written rx within 72 hours Schedule II No existing rx Remember no C-II refills (in the event patient had prior rx) Must be an emergency Must be communicated by prescriber May dispense up to 72 hour supply Create a written rx/order Prescriber must provided written rx within 7 days. 7

8 Emergency Dispensing Questions? Naloxone ALA. Code Opioid Antagonist Prescriptions; Administration; Liability. Opioid antagonist ( ) means naloxone hydrochloride or other similarly acting drug that is approved by the federal Food and Drug Administration for the treatment of opioid overdose. Opioids Prescription opioids are powerful pain-reducing medications that include prescription oxycodone, hydrocodone and morphine, among others, and have both benefits as well as potentially serious risks. These medications can help manage pain when prescribed for the right condition and when used properly. But when misused or abused, they can cause serious harm, including addiction, overdose and death. FDA.gov: Opioid Medications. 8

9 Opioid Overdose Due to their (opioids) effect on the part of the brain which regulates breathing, opioids in high doses can cause respiratory depression and death. An opioid overdose can be identified by a combination of three signs and symptoms referred to as the opioid overdose triad. The symptoms of the triad are: pinpoint pupils Unconsciousness respiratory depression. Opioid Overdose This is a medical emergency call 911. Seventy-eight (78) people in the U.S. die every day from an opioid overdose, according to the Centers for Disease Control and Prevention (CDC). June 6, 2016 U.S. News & World Report Prince On June 2, 2016, the Midwest Medical Examiner s Office in Ramsey, MN, reported that Prince, age 57, died from accidental fentanyl toxicity (opioid overdose). U.S. News & World report used the following statement to describe the drug fentanyl: Fentanyl, a prescription opioid drug used to treat severe pain, carries a high risk for addiction and dependence; Prince was reportedly taking it for hip pain. 9

10 Opioid Overdose/Naloxone A physician or dentist acting in good faith may directly or by standing order prescribe and a pharmacist may dispense an opioid antagonist to either of the following: Individual at risk Family member, friend or other individual (police officer) in position to assist Opioid Overdose/Naloxone The physician or dentist (prior to dispensing) may require: Written communication providing a factual basis for a reasonable conclusion to either of: Individual seeking help is at risk The individual other than the individual at risk of experiencing the overdose and who is seeking the opioid antagonist is in relation to the individual at risk as a family member, friend or otherwise in a position to assist. In other words, the physician or dentist wants to make sure the reason falls within Opioid Overdose/Naloxone If the individual that administers the naloxone has a good faith belief that the individual is experiencing an opioid overdose they may administer the naloxone. They are immune from any civil or criminal liability. They must receive basic instructions and information on how to administer the opioid antagonist. 10

11 Opioid Overdose/Naloxone Keep in mind that if you do this you may be dispensing a drug for use in an individual that is NOT your patient. You are providing instructions to someone that will need to use the naloxone in an emergency situation where they may NOT be thinking clearly. Make sure you conduct proper education and maintain appropriate documentation. Liability Concerns? Make sure you are dispense the naloxone pursuant to a protocol/standing order or prescription. Have a solid education program don t just give the purchaser a handout. Consider video training or one on one training to supplement the handouts. Document, document, document Naloxone Does naloxone have side effects? What warnings should you give to the purchaser. Yes, we want to prevent an overdose but do patients have potential adverse reactions when they do not have access to drug? 11

12 Possible Agitation? Make Sure The purchaser knows that this is a medical emergency and that they should call 911! Even if you don t believe they will call 911 advise them to call 911! The family or patient knows that naloxone is not a cure all. The underlying problem of addiction still exists. Opioid Withdrawal Early symptoms of withdrawal include: Agitation Anxiety Muscle aches Increased tearing Insomnia Runny nose Sweating Yawning 12

13 Opioid Withdrawal Late symptoms of withdrawal include: Abdominal cramping Diarrhea Dilated pupils Goose bumps Nausea Vomiting y/article/ htm. June 3, Questions Are you required to dispense naloxone? Which of the following is true regarding the dispensing of naloxone? You must follow the protocol or standing order of a physician, dentist or mid-level practitioner? You can only dispense to an individual that is using an opioid or is addicted to opioids? THANK YOU! 13

14 Thank You APA Ronda H. Lacey, J.D., M.S. Pharm. 14

AHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion

AHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion Fraud and Compliance Forum, October 2017. Click here to access audio. AHLA X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion Michelle Bergholz Frazier Senior Vice President,

More information

PART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition)

PART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition) 1305.16 1305.16 Special procedure for filling certain order forms. (a) The purchaser of carfentanil etorphine hydrochloride or diprenorphine shall submit copy 1 and 2 of the order form to the supplier

More information

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26)

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26) H GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH0-MGfa-H* (01/) H.B. Mar, HOUSE PRINCIPAL CLERK D Short Title: Strengthen Opioid Misuse Prevention (STOP)Act. (Public) Sponsors: Referred to:

More information

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION

SIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2017 GENERAL SESSION AN ACT relating to public health and safety; creating the Emergency Administration of Opiate Antagonist Act; providing for prescription and administration of an opiate antagonist drug as specified; granting

More information

SENATE FILE NO. SF0042. Sponsored by: Joint Judiciary Interim Committee A BILL. for. AN ACT relating to public health and safety; creating the

SENATE FILE NO. SF0042. Sponsored by: Joint Judiciary Interim Committee A BILL. for. AN ACT relating to public health and safety; creating the 0 STATE OF WYOMING LSO-000 SENATE FILE NO. SF00 Opiate overdose emergency treatment. Sponsored by: Joint Judiciary Interim Committee A BILL for AN ACT relating to public health and safety; creating the

More information

National Council on Patient Information and Education

National Council on Patient Information and Education National Council on Patient Information and Education You are not alone The type of pain that caused your doctor to prescribe a pain medicine for you can make you feel that you are different from everyone

More information

A Bill Regular Session, 2015 SENATE BILL 717

A Bill Regular Session, 2015 SENATE BILL 717 Stricken language would be deleted from and underlined language would be added to present law. 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session, SENATE BILL By: Senator

More information

A Bill Regular Session, 2015 SENATE BILL 880

A Bill Regular Session, 2015 SENATE BILL 880 Stricken language would be deleted from and underlined language would be added to present law. Act of the Regular Session 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session,

More information

3 By Representatives Sells, Weaver, Harper, South, McCutcheon, 4 Harbison, Butler, Mooney, Hanes, Williams (JW), Wilcox, Scott,

3 By Representatives Sells, Weaver, Harper, South, McCutcheon, 4 Harbison, Butler, Mooney, Hanes, Williams (JW), Wilcox, Scott, 1 HB379 2 175235-1 3 By Representatives Sells, Weaver, Harper, South, McCutcheon, 4 Harbison, Butler, Mooney, Hanes, Williams (JW), Wilcox, Scott, 5 Givan, Rogers, Moore (M), Ingram, Polizos, Baker and

More information

SECTION PRESCRIPTIONS

SECTION PRESCRIPTIONS SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or

More information

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Dispensing and administration of emergency opioid antagonist without a

Dispensing and administration of emergency opioid antagonist without a 68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies

More information

Naloxone Access Statutes

Naloxone Access Statutes Naloxone Access Statutes Research current through March 1, 2016 This project was supported by Grant No. G15599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions

More information

Sub. S.B. 119 As Passed by the Senate

Sub. S.B. 119 As Passed by the Senate AM3404 Sub. S.B. 119 As Passed by the Senate Topic: Opioid Data and Communication Expansion Act moved to amend as follows: In line 1 of the title, after "4723.52," insert "4729.01, 4729.44, 4729.75, 4729.79,

More information

Prescription Monitoring Program (PMP)

Prescription Monitoring Program (PMP) 06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid

More information

Rule Governing the Prescribing of Opioids for Pain

Rule Governing the Prescribing of Opioids for Pain Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This

More information

California. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION Chapter NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION EFFECTIVE: Policy REVISED: 4/13/9 draft NALOXONE DISTRIBUTION POLICY I. PURPOSE: This New Mexico Department of Health (NMDOH)

More information

POWER TO HELP REVERSE AN OPIOID OVERDOSE

POWER TO HELP REVERSE AN OPIOID OVERDOSE POWER TO HELP REVERSE AN OPIOID OVERDOSE FDA APPROVED Concentrated 4 mg dose Needle-free; no assembly required Designed for ease-of-use in the community setting Requires no specialized training* Not a

More information

North Dakota Board of Pharmacy

North Dakota Board of Pharmacy North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives

More information

Michigan Opioid Legislation Hospital Compliance Checklist

Michigan Opioid Legislation Hospital Compliance Checklist MHA KEYSTONE CENTER MICHIGAN OPIOID LEGISLATION HOSPITAL COMPLIANCE CHECKLIST The Michigan Opioid Legislation was created by the Michigan Health & Hospital Association to help guide its member hospitals

More information

Legal Issues in Opioid Prescribing

Legal Issues in Opioid Prescribing Legal Issues in Opioid Prescribing Joanne L. Martin, J.D. Legal Counsel Mayo Clinic Rochester, Mn 2015 MFMER slide-1 Conflict of Interest I have no relevant financial relationships to disclose I will not

More information

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

Vermont. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of

More information

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243 GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW 2017-74 HOUSE BILL 243 AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS;

More information

1 HB By Representative Williams (JD) 4 RFD: Health. 5 First Read: 09-JAN-18 6 PFD: 11/28/2017. Page 0

1 HB By Representative Williams (JD) 4 RFD: Health. 5 First Read: 09-JAN-18 6 PFD: 11/28/2017. Page 0 1 HB37 2 188862-1 3 By Representative Williams (JD) 4 RFD: Health 5 First Read: 09-JAN-18 6 PFD: 11/28/2017 Page 0 1 188862-1:n:11/16/2017:PMG/tj LSA2017-3516 2 3 4 5 6 7 8 SYNOPSIS: This bill would establish

More information

Referred to Committee on Health and Human Services. SUMMARY Establishes an opioid overdose prevention policy for Nevada.

Referred to Committee on Health and Human Services. SUMMARY Establishes an opioid overdose prevention policy for Nevada. S.B. SENATE BILL NO. COMMITTEE ON HEALTH AND HUMAN SERVICES (ON BEHALF OF THE GOVERNOR) MARCH, 0 Referred to Committee on Health and Human Services SUMMARY Establishes an opioid overdose prevention policy

More information

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any

More information

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions Research current through January 21, 2015 This project was supported by Grant No. G1399ONDCP03A, awarded by the Office

More information

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217 SESSION OF 2017 SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217 As Amended by House Committee on Health and Human Services Brief* HB 2217, as amended, would enact new law and amend the Kansas Pharmacy Act (Act)

More information

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine The purpose of this agreement is to give you information about the medications you will be taking for

More information

PROPOSED AMENDMENTS TO HOUSE BILL 3440

PROPOSED AMENDMENTS TO HOUSE BILL 3440 HB 0- (LC ) // (MBM/ps) Requested by Representative WILLIAMSON PROPOSED AMENDMENTS TO HOUSE BILL 0 1 On page 1 of the printed bill, line, delete 1A. and. Delete lines through and pages through and insert:

More information

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

2016 Dr. Douglas H. Kay CPE Symposium

2016 Dr. Douglas H. Kay CPE Symposium GREGORY CAMERON, R.Ph ASSISTANT PROFESSOR OF PHARMACY PRACTICE FIELD COORDINATOR COMMUNITY SITES HUSSON UNIVERSITY SCHOOL OF PHARMACY November 5, 2016 Please Silence All Electronic Equipment OBJECTIVES

More information

BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director

BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director BOARD OF PHARMACY- REGULATORY UPDATE Kimberly Grinston, J.D., Executive Director Disclosure and Conflict of Interest I declare no conflicts of interest, real or apparent, and no financial interest in any

More information

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical

More information

Strategies to Manage The Opioid Crisis

Strategies to Manage The Opioid Crisis Strategies to Manage The Opioid Crisis Matt Feehery, LCDC Senior Vice President & CEO PaRC (Prevention & Recovery Center) Behavioral Health Services February 1, 2018 A Pill for Your Pain But my doctor

More information

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions Research current through March 23, 2015 This project was supported by Grant No. G1399ONDCP03A, awarded by the Office of

More information

Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain

Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain Taking Opioids Responsibly for Your Safety and the Safety of Others: Patient Information Guide on Long-term Opioid Therapy for Chronic Pain Department of Veterans Affairs (VA) and Department of Defense

More information

WHAT YOU NEED TO KNOW TO ABOUT AB 474

WHAT YOU NEED TO KNOW TO ABOUT AB 474 WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov

More information

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able

More information

Campus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING

Campus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING Campus Narcan Project OPIOID OVERDOSE FIRST RESPONDER TRAINING Opioid Epidemic Prescription Opiods Can be prescribed by doctors to treat moderate to severe pain, but can also have serious risks and side

More information

Be it enacted by the People of the State of Illinois,

Be it enacted by the People of the State of Illinois, AN ACT concerning education. Be it enacted by the People of the State of Illinois, represented in the General Assembly: Section 5. The School Code is amended by changing Section 22-30 as follows: (105

More information

Today s Presenters. Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care

Today s Presenters. Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care 203 - Monday, April 16, 2018 Today s Presenters Ben Purser Former F.B.I. Special Agent Donna Thiel ProviderTrust Chief

More information

MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution

MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and

More information

SUBJECT: Opioid Overdose and Intranasal Naloxone Training for Law Enforcement: Train the Trainer Session: Queens County October 17, 2014

SUBJECT: Opioid Overdose and Intranasal Naloxone Training for Law Enforcement: Train the Trainer Session: Queens County October 17, 2014 ANDREW M. CUOMO GOVERNOR STATE OF NEW YORK DIVISION OF CRIMINAL JUSTICE SERVICES Alfred E. Smith Office Building 80 South Swan Street Albany, New York 12210 http://criminaljustice.ny.gov MICHAEL C. GREEN

More information

MEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only

MEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only MEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency

More information

Student Number. PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION 2 November 10, 1999

Student Number. PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION 2 November 10, 1999 PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION 2 November 10, 1999 Questions 1-25 are multiple choice; please record answers on Side 2 of a Standard Answer Sheet, Form 1158. Follow the instructions

More information

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Virginia. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Teaching Objectives Describe the balance a that must be sought in the treatment of pain and the prevention of drug diversion. Discuss regulatory polic

Teaching Objectives Describe the balance a that must be sought in the treatment of pain and the prevention of drug diversion. Discuss regulatory polic Preventing Controlled Substance Diversion David B. Brushwood, R.Ph.,., J.D. Professor of Pharmaceutical Outcomes & Policy The University of Florida Teaching Objectives Describe the balance a that must

More information

MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP

MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP IMPORTANT: Keep oxycodone hydrochloride oral solution in a safe place away from children. Accidental use by a child is

More information

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution

MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution IMPORTANT: Keep morphine sulfate oral solution in a safe place away from children. Accidental use by a child is a medical emergency

More information

Naloxone Access Statutes

Naloxone Access Statutes Naloxone Access Statutes Research current through August 30, 2015 This project was supported by Grant No. G15599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions

More information

ACCG Mental Health Summit

ACCG Mental Health Summit ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities

More information

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New

More information

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System Controlled Substance Prescribing: A Physician s Guide Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System Objectives Review schedules of controlled substances and their propensity for

More information

Protocol For: Personally Furnishing Naloxone. Update Log

Protocol For: Personally Furnishing Naloxone. Update Log Protocol For: Personally Furnishing Naloxone Update Log Updated By: Reason for Update: Date: Approved By: K. Benick RN Original draft 6/7/16 Pam Butler Protocol: Personally Furnishing Naloxone_Morrow County

More information

CRITICAL POLICY REFERENCE MANUAL FILE CODE: X Monitored X Mandated Sample Policy X Other Reasons

CRITICAL POLICY REFERENCE MANUAL FILE CODE: X Monitored X Mandated Sample Policy X Other Reasons CRITICAL POLICY REFERENCE MANUAL FILE CODE: 5141.21 X Monitored X Mandated Sample Policy X Other Reasons ADMINISTERING MEDICATION The board shall not be responsible for the diagnosis and treatment of student

More information

Ahsan U. Rashid, M.D., F.A.C.P.

Ahsan U. Rashid, M.D., F.A.C.P. Ahsan U. Rashid, M.D., F.A.C.P. OPIOID MAINTENANCE AND CONSENT Instructions: Review this document before signing. This document will help both the patient and caregivers in establishing a medical program

More information

The Wisconsin Prescription Drug Monitoring Program

The Wisconsin Prescription Drug Monitoring Program The Wisconsin Prescription Drug Monitoring Program DHS 2018 WI Opioid Forum April 12, 2018 Learning Objectives 1. How the WI epdmp supports healthcare professionals in making informed prescribing, dispensing

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

What is the most important information I should know about Morphine Sulfate Oral Solution?

What is the most important information I should know about Morphine Sulfate Oral Solution? Medication Guide MORPHINE SULFATE (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and

More information

[First Reprint] ASSEMBLY, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 4, 2016

[First Reprint] ASSEMBLY, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 4, 2016 [First Reprint] ASSEMBLY, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED FEBRUARY, 0 Sponsored by: Assemblyman DANIEL R. BENSON District (Mercer and Middlesex) Assemblywoman VALERIE VAINIERI HUTTLE

More information

The Missouri Opioid-Heroin Overdose Prevention and Education (MO-HOPE) Project Mission: to reduce opioid overdose deaths in Missouri through expanded

The Missouri Opioid-Heroin Overdose Prevention and Education (MO-HOPE) Project Mission: to reduce opioid overdose deaths in Missouri through expanded The Missouri Opioid-Heroin Overdose Prevention and Education (MO-HOPE) Project Mission: to reduce opioid overdose deaths in Missouri through expanded access to naloxone, overdose education, prevention,

More information

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Clint Ross, PharmD, BCPP Clinical Pharmacy Specialist Psychiatry Residency Program Director Psychiatric Pharmacy Medical University

More information

ORAL MEDS FOR PAIN. Pain Tolerance 4/11/2018

ORAL MEDS FOR PAIN. Pain Tolerance 4/11/2018 ORAL MEDS FOR PAIN Pain Tolerance Varies with each individual Signs usually should match symptoms Have compassion but don t panic when someone appears to be in pain 1 The Psychology of Pain A firm, calm,

More information

OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN

OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN ANTOINETTE BROWN, RPH LAUREL RAMER, 2019 PHARMD CANDIDATE 2018 WYOMING CONFERENCE ON AGING LARAMIE, WY OCTOBER 3, 2018 OBJECTIVES 1. Understand the

More information

Prescription Opioid Overdose in Oregon: A public health perspective

Prescription Opioid Overdose in Oregon: A public health perspective Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,

More information

Law Enforcement Naloxone Training Florida Department of Children and Families. Office of Substance Abuse and Mental Health

Law Enforcement Naloxone Training Florida Department of Children and Families. Office of Substance Abuse and Mental Health Protecting, Leading, Uniting Since 1893 Law Enforcement Naloxone Training Florida Department of Children and Families Office of Substance Abuse and Mental Health 1. Learn how to recognize and respond to

More information

MEDICATION MANAGEMENT AGREEMENT

MEDICATION MANAGEMENT AGREEMENT MEDICATION MANAGEMENT AGREEMENT The goal of this agreement is to ensure that you and your physician comply with all state and federal regulations concerning the prescribing of controlled substances. The

More information

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update Bureau of Professional Licensing MAPS Updates & Opportunities April 28, 2018 Presented by Andrew Hudson, Manager Haley Winans, Analyst Drug Monitoring Section Bureau of Professional Licensing BPL-MAPS@Michigan.gov

More information

Objectives 1/25/18. An Update on Controlled Substance Prescribing Laws & Rules for CNMs. Exclusionary Formulary Effective: May 17, 2017

Objectives 1/25/18. An Update on Controlled Substance Prescribing Laws & Rules for CNMs. Exclusionary Formulary Effective: May 17, 2017 1/25/18 An Update on Controlled Substance Prescribing Laws & Rules for CNMs Keeley Harding, DNP, APRN, CPNP-AC/PC February 4, 2018 2018 Ohio ACNM Forward Kalahari Resorts and Conference Center, Sandusky,

More information

PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998

PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998 PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998 Questions 1 20 are multiple choice; please record answers on Side 2 of a Standard Answer Sheet, Form 1158. Follow the instructions

More information

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent Pain may be effectively managed through the use of controlled substance medications (referred to below as opioids

More information

Tuscarawas County Health Department. Vivitrol Treatment Consent

Tuscarawas County Health Department. Vivitrol Treatment Consent Tuscarawas County Health Department Vivitrol Treatment Consent I. Vivitrol Medication Guide: a. VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) b. Read this Medication Guide

More information

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director

More information

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place

More information

ASSEMBLY, No. 542 STATE OF NEW JERSEY. 218th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 2018 SESSION

ASSEMBLY, No. 542 STATE OF NEW JERSEY. 218th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 2018 SESSION ASSEMBLY, No. STATE OF NEW JERSEY th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 0 SESSION Sponsored by: Assemblyman VINCENT MAZZEO District (Atlantic) Assemblyman JOSEPH A. LAGANA District (Bergen and

More information

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Let s Talk About. Pain Medicines. wisconsin. health literacy. A division of Wisconsin Literacy, Inc.

Let s Talk About. Pain Medicines. wisconsin. health literacy. A division of Wisconsin Literacy, Inc. Let s Talk About Pain Medicines wisconsin health literacy A division of Wisconsin Literacy, Inc. How are prescription opioids different than other pain medicines? People think of opioids as illegal drugs,

More information

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description

More information

Liability, Informed Consent, and Risk Management 15 Thoughts for Pain Management Physicians

Liability, Informed Consent, and Risk Management 15 Thoughts for Pain Management Physicians Liability, Informed Consent, and Risk Management 15 Thoughts for Pain Management Physicians Click to edit Master title style Presented by: Scott Becker, JD, CPA, Partner, Publisher Becker Healthcare 14th

More information

Pennsylvania DEPARTMENT OF HEALTH

Pennsylvania DEPARTMENT OF HEALTH Pennsylvania DEPARTMENT OF HEALTH Updated: 01/10/2018 XI. XII. KEY INFORMATION 1. If you believe, someone is experiencing an opioid overdose, call 911! 2. Remain with the person until first responders

More information

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin. The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp

More information

NC General Statutes - Chapter 90 Article 5E 1

NC General Statutes - Chapter 90 Article 5E 1 Article 5E. North Carolina Controlled Substances Reporting System Act. 90-113.70. Short title. This Article shall be known and may be cited as the "North Carolina Controlled Substances Reporting System

More information

Naloxone Administration Training

Naloxone Administration Training Naloxone Administration Training Welcome! Welcome to the online training for naloxone administration The Presenter Dr. Joe Parks, Medical Director, Distinguished Professor, Missouri Institute for Mental

More information

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid

More information

MEDICATION GUIDE CODEINE SULFATE (koh-deen) CII Oral Solution

MEDICATION GUIDE CODEINE SULFATE (koh-deen) CII Oral Solution MEDICATION GUIDE CODEINE SULFATE (koh-deen) CII Oral Solution IMPORTANT: Do not give CODEINE Sulfate Oral Solution to a child to treat pain after tonsillectomy or adenoidectomy surgery. When you take CODEINE

More information

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last

More information

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Utah. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Utah Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view

More information

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good PAIN MEDICINE Volume 5 Number 3 2004,* Edward Covington, MD, and Patricia M. Good *Georgetown University, Washington, District of Columbia; Cleveland Clinic Foundation, Cleveland, Ohio; Office of Diversion

More information

The Impact of Opioid Use and Abuse on Medical Community, Businesses, Social Organizations and Individiuals and Their Families

The Impact of Opioid Use and Abuse on Medical Community, Businesses, Social Organizations and Individiuals and Their Families The Impact of Opioid Use and Abuse on Medical Community, Businesses, Social Organizations and Individiuals and Their Families THE MAGNITUDE OF THE OPIOID EPIDEMIC THE COSTS TO LOCAL, STATE AND NATIONAL

More information

FEDERAL & STATE LAWS RELATED TO THE PRESCRIBING OF CONTROLLED SUBSTANCES LEONARD SCHUCHMAN, DO, MPH, FAAFP PRESIDENT- ELECT, NJAOPS

FEDERAL & STATE LAWS RELATED TO THE PRESCRIBING OF CONTROLLED SUBSTANCES LEONARD SCHUCHMAN, DO, MPH, FAAFP PRESIDENT- ELECT, NJAOPS FEDERAL & STATE LAWS RELATED TO THE PRESCRIBING OF CONTROLLED SUBSTANCES LEONARD SCHUCHMAN, DO, MPH, FAAFP PRESIDENT- ELECT, NJAOPS OBJECTIVES Review of the applicable laws and rules both Federal and for

More information

Prescribing and Dispensing Drugs

Prescribing and Dispensing Drugs STANDARDS & GUIDELINES Prescribing and Dispensing Drugs TABLE OF CONTENTS Standards and guidelines inform practitioners and the public of CDSBC s expectations for registrants. This document primarily contains

More information

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid

More information

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017 Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial

More information

Naloxone and Combating the Opioid Epidemic

Naloxone and Combating the Opioid Epidemic Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to

More information

Naloxone Standing Order for Opioid Overdose

Naloxone Standing Order for Opioid Overdose Naloxone Standing Order for Opioid Overdose By: Christine Trusky, PharmD Candidate 2016, Wilkes University Continuing Education Activity Details: Activity Type: Knowledge-based Target Audience: Pharmacists

More information